Consensus care recommendations for alfapump ® in cirrhotic patients with refractory or recurrent ascites.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100968547 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-230X (Electronic) Linking ISSN: 1471230X NLM ISO Abbreviation: BMC Gastroenterol Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
      Ascites*/etiology ; Ascites*/therapy ; Liver Cirrhosis*/complications ; Liver Cirrhosis*/surgery; Humans ; Paracentesis ; Urinary Bladder
    • Abstract:
      Background: The alfapump ® is an implantable class III medical device that pumps ascitic fluid from the peritoneal space to the urinary bladder from where it is excreted. The pump reduces or abrogates the need for repeated paracentesis in patients with recurrent or refractory ascites.
      Aims: To improve outcomes for alfapump ® implantation and pre- and post-implant patient management in both clinical trial and real-world settings by development of consensus recommendations.
      Methods: The alfapump ® working group consisting of hepatologists and surgeons with extensive experience in implantation of the alfapump ® and patient management met on two occasions: (1) to determine the key areas where recommendations should be made; and (2) to discuss the experiences of the working group within those areas and formulate draft statements. Developed statements were submitted to the group and consensus sought on relevance and wording through a collaborative iterative approach in order to consolidate the recommendations into consensus statements. Only recommendations agreed upon unanimously were included.
      Results: Twenty-three consensus recommendations were developed in the areas of pre-implantation procedure, (three statements), surgical implant procedure (11 statements), immediate post-implant care (three statements) and long-term management (six statements).
      Conclusions: The consensus statements are a valuable reference resource for physicians managing patients with the alfapump ® and for those considering management strategies for patients with refractory ascites.
      (© 2022. The Author(s).)
    • References:
      Hepatology. 2021 Aug;74(2):1014-1048. (PMID: 33942342)
      Gut. 2006 Oct;55 Suppl 6:vi1-12. (PMID: 16966752)
      J Hepatol. 2017 Nov;67(5):940-949. (PMID: 28645737)
      J Hepatol. 2018 Aug;69(2):406-460. (PMID: 29653741)
      BMC Palliat Care. 2019 Dec 5;18(1):109. (PMID: 31805921)
      Liver Int. 2018 Feb;38 Suppl 1:126-133. (PMID: 29427501)
      J Hepatol. 2019 Jan;70(1):172-193. (PMID: 30144956)
      Aliment Pharmacol Ther. 2017 Nov;46(10):981-991. (PMID: 28940225)
      Aliment Pharmacol Ther. 2019 Nov;50(9):978-987. (PMID: 31583729)
      Eur J Gastroenterol Hepatol. 2018 Sep;30(9):1082-1089. (PMID: 29738325)
      J Hepatol. 2013 May;58(5):922-7. (PMID: 23318604)
      Liver Transpl. 2020 May;26(5):651-661. (PMID: 31999044)
      Gut. 2021 Jan;70(1):9-29. (PMID: 33067334)
      J Vasc Interv Radiol. 2020 Aug;31(8):1256-1262.e3. (PMID: 32654961)
      Liver Transpl. 2017 May;23(5):583-593. (PMID: 28318147)
      Langenbecks Arch Surg. 2020 Feb;405(1):117-123. (PMID: 31915920)
    • Contributed Indexing:
      Keywords: Alfapump; Ascites; Cirrhosis; Implantation; Long-term antibiotics; Medical device; Paracentesis; Patient management; Refractory ascites; TIPSS
    • Publication Date:
      Date Created: 20220309 Date Completed: 20220310 Latest Revision: 20220531
    • Publication Date:
      20231215
    • Accession Number:
      PMC8905806
    • Accession Number:
      10.1186/s12876-022-02173-5
    • Accession Number:
      35260086